For instance, third-generation EGFR TKIs are being developed as part of a strategy to overcome treatment resistance to first- and second-generation EGFR TKIs in lung cancer patients [102]; however, resistance to third-generation EGFT TKIs such as AZD9291 and HM61713 are also being arise [103]. This evidence concerns the gene EGFR and lung carcinoma.